

# Kenneth K Tanabe

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8100499/publications.pdf>

Version: 2024-02-01

146  
papers

8,676  
citations

46984

47  
h-index

48277

88  
g-index

149  
all docs

149  
docs citations

149  
times ranked

12329  
citing authors

#	ARTICLE	IF	CITATIONS
1	Frequent Mutation of Isocitrate Dehydrogenase <i>(IDH)1</i> and <i>IDH2</i> in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping. <i>Oncologist</i> , 2012, 17, 72-79.	1.9	629
2	Treatment of intrahepatic malignancy with radiofrequency ablation. <i>Cancer</i> , 2000, 88, 2452-2463.	2.0	583
3	Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. <i>Journal of Clinical Oncology</i> , 2016, 34, 460-468.	0.8	363
4	Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 367-402.	2.3	326
5	Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. <i>Hepatology</i> , 2014, 59, 1577-1590.	3.6	290
6	Epithelial-to-Mesenchymal Transition and Integrin-Linked Kinase Mediate Sensitivity to Epidermal Growth Factor Receptor Inhibition in Human Hepatoma Cells. <i>Cancer Research</i> , 2008, 68, 2391-2399.	0.4	287
7	Prognostic and Therapeutic Implications of Microvascular Invasion in Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 1474-1493.	0.7	255
8	TAS-120 Overcomes Resistance to ATP-Competitive FGFR Inhibitors in Patients with FGFR2 Fusion-Positive Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2019, 9, 1064-1079.	7.7	254
9	Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma. <i>Cell Metabolism</i> , 2019, 29, 174-182.e5.	7.2	246
10	The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: A comprehensive and evidence-based comparison and review. <i>Cancer</i> , 2014, 120, 2824-2838.	2.0	212
11	Morbidity and Mortality after Liver Resection: Results of the Patient Safety in Surgery Study. <i>Journal of the American College of Surgeons</i> , 2007, 204, 1284-1292.	0.2	207
12	Detection of microscopic melanoma metastases in sentinel lymph nodes. , 1999, 86, 617-627.		192
13	Epidermal Growth Factor Gene Functional Polymorphism and the Risk of Hepatocellular Carcinoma in Patients With Cirrhosis. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 53-60.	3.8	183
14	Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition. <i>Cancer Cell</i> , 2016, 30, 879-890.	7.7	172
15	PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 470-478.	3.2	168
16	Mouse model of carbon tetrachloride induced liver fibrosis: Histopathological changes and expression of CD133 and epidermal growth factor. <i>BMC Gastroenterology</i> , 2010, 10, 79.	0.8	151
17	Melanoma in the young: Differences and similarities with adult melanoma. <i>Cancer</i> , 2007, 110, 614-624.	2.0	144
18	Melanoma, Version 2.2013. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 395-407.	2.3	134

#	ARTICLE	IF	CITATIONS
19	A Functional Polymorphism in the Epidermal Growth Factor Gene Is Associated With Risk for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2011, 141, 141-149.	0.6	133
20	Molecular MRI of collagen to diagnose and stage liver fibrosis. <i>Journal of Hepatology</i> , 2013, 59, 992-998.	1.8	128
21	Viral Oncolysis. <i>Oncologist</i> , 2002, 7, 106-119.	1.9	122
22	Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 250-275.	2.3	120
23	Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. <i>Oncologist</i> , 2015, 20, 1019-1027.	1.9	112
24	An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. <i>FASEB Journal</i> , 2000, 14, 301-311.	0.2	107
25	Surgical Treatment and Other Regional Treatments for Colorectal Cancer Liver Metastases. <i>Oncologist</i> , 1999, 4, 197-208.	1.9	104
26	Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma. <i>Cancer Research</i> , 2019, 79, 4326-4330.	0.4	99
27	Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 64-72.	0.4	99
28	Molecular MR imaging of liver fibrosis: A feasibility study using rat and mouse models. <i>Journal of Hepatology</i> , 2012, 57, 549-555.	1.8	97
29	Molecular Magnetic Resonance Imaging Using a Redox-Active Iron Complex. <i>Journal of the American Chemical Society</i> , 2019, 141, 5916-5925.	6.6	96
30	Enhancement of Gene Therapy Specificity for Diffuse Colon Carcinoma Liver Metastases with Recombinant Herpes Simplex Virus. <i>Annals of Surgery</i> , 1996, 224, 323-330.	2.1	83
31	Phase II Study of Proton-Based Stereotactic Body Radiation Therapy for Liver Metastases: Importance of Tumor Genotype. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	82
32	A Functional Epidermal Growth Factor (EGF) Polymorphism, EGF Serum Levels, and Esophageal Adenocarcinoma Risk and Outcome. <i>Clinical Cancer Research</i> , 2008, 14, 3216-3222.	3.2	80
33	Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. <i>Cancer</i> , 2002, 95, 1171-1181.	2.0	73
34	Cancer Gene Therapy Using a Replication-Competent Herpes Simplex Virus Type 1 Vector. <i>Annals of Surgery</i> , 1998, 228, 366-374.	2.1	73
35	Radiofrequency ablation. <i>Cancer</i> , 2004, 100, 641-650.	2.0	72
36	Outcome of patients with de novo versus nevus-associated melanoma. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 54-58.	0.6	71

#	ARTICLE	IF	CITATIONS
37	Using Smartphones to Capture Novel Recovery Metrics After Cancer Surgery. <i>JAMA Surgery</i> , 2020, 155, 123.	2.2	71
38	Involvement of CD44 in matrix metalloproteinase-2 regulation in human melanoma cells. , 1999, 80, 387-395.		70
39	Metformin prevents hepatocellular carcinoma development by suppressing hepatic progenitor cell activation in a rat model of cirrhosis. <i>Cancer</i> , 2016, 122, 1216-1227.	2.0	65
40	Melanoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 366-400.	2.3	63
41	Hepatocellular carcinoma: early-stage management challenges. <i>Journal of Hepatocellular Carcinoma</i> , 2017, Volume 4, 81-92.	1.8	60
42	Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy. <i>DMM Disease Models and Mechanisms</i> , 2018, 11, .	1.2	60
43	3D molecular MR imaging of liver fibrosis and response to rapamycin therapy in a bile duct ligation rat model. <i>Journal of Hepatology</i> , 2015, 63, 689-696.	1.8	57
44	Targeting clinical epigenetic reprogramming for chemoprevention of metabolic and viral hepatocellular carcinoma. <i>Gut</i> , 2021, 70, 157-169.	6.1	57
45	Molecular imaging of oxidized collagen quantifies pulmonary and hepatic fibrogenesis. <i>JCI Insight</i> , 2017, 2, .	2.3	57
46	The impact of primary tumor size, lymph node status, and other prognostic factors on the risk of cancer death. <i>Cancer</i> , 2009, 115, 5071-5083.	2.0	55
47	Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges. <i>Current Cancer Drug Targets</i> , 2012, 12, 1129-59.	0.8	55
48	T2 relaxation time is related to liver fibrosis severity. <i>Quantitative Imaging in Medicine and Surgery</i> , 2016, 6, 103-114.	1.1	54
49	Choices of Therapeutic Strategies for Colorectal Liver Metastases Among Expert Liver Surgeons. <i>Annals of Surgery</i> , 2020, 272, 715-722.	2.1	53
50	CD44s expression in human colon carcinomas influences growth of liver metastases. <i>International Journal of Cancer</i> , 2000, 85, 523-526.	2.3	48
51	A novel chemoradiation targeting stem and nonstem pancreatic cancer cells by repurposing disulfiram. <i>Cancer Letters</i> , 2017, 409, 9-19.	3.2	48
52	Molecular magnetic resonance imaging accurately measures the antifibrotic effect of EDP-305, a novel farnesoid X receptor agonist. <i>Hepatology Communications</i> , 2018, 2, 821-835.	2.0	46
53	Tumor Contrast Enhancement and Whole-Body Elimination of the Manganese-Based Magnetic Resonance Imaging Contrast Agent Mn-PyC3A. <i>Investigative Radiology</i> , 2019, 54, 697-703.	3.5	45
54	Combined magnetic resonance elastography and collagen molecular magnetic resonance imaging accurately stage liver fibrosis in a rat model. <i>Hepatology</i> , 2017, 65, 1015-1025.	3.6	43

#	ARTICLE	IF	CITATIONS
55	CM-101: Type I Collagen-targeted MR Imaging Probe for Detection of Liver Fibrosis. <i>Radiology</i> , 2018, 287, 581-589.	3.6	43
56	A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors. <i>Practical Radiation Oncology</i> , 2014, 4, 316-322.	1.1	42
57	Molecular signatures in hepatocellular carcinoma: A step toward rationally designed cancer therapy. <i>Cancer</i> , 2018, 124, 3084-3104.	2.0	42
58	The Clinical Management of Cholangiocarcinoma in the United States and Europe: A Comprehensive and Evidence-Based Comparison of Guidelines. <i>Annals of Surgical Oncology</i> , 2021, 28, 2660-2674.	0.7	38
59	Oncolysis by viral replication and inhibition of angiogenesis by a replication-conditional herpes simplex virus that expresses mouse endostatin. <i>Cancer</i> , 2004, 101, 869-877.	2.0	36
60	Viral oncolysis by herpes simplex virus and other viruses. <i>Cancer Biology and Therapy</i> , 2005, 4, 524-531.	1.5	36
61	Positron Emission Tomography of Herpes Simplex Virus 1 Oncolysis. <i>Cancer Research</i> , 2007, 67, 3295-3300.	0.4	35
62	A Multidisciplinary Team Approach for Triage of Elective Cancer Surgery at the Massachusetts General Hospital During the Novel Coronavirus COVID-19 Outbreak. <i>Annals of Surgery</i> , 2020, 272, e20-e21.	2.1	33
63	Management implications of fluorodeoxyglucose positron emission tomography/magnetic resonance in untreated intrahepatic cholangiocarcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1871-1884.	3.3	32
64	Facility Type is Associated with Margin Status and Overall Survival of Patients with Resected Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2019, 26, 4091-4099.	0.7	31
65	Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively through Turbulence and Change. <i>Annals of Surgical Oncology</i> , 2020, 27, 2600-2613.	0.7	31
66	Pioglitazone Reduces Hepatocellular Carcinoma Development in Two Rodent Models of Cirrhosis. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 101-111.	0.9	30
67	Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 1122-1129.	0.7	29
68	Fibrotic Response to Neoadjuvant Therapy Predicts Survival in Pancreatic Cancer and Is Measurable with Collagen-Targeted Molecular MRI. <i>Clinical Cancer Research</i> , 2020, 26, 5007-5018.	3.2	29
69	Risk Factors, Pathogenesis, and Strategies for Hepatocellular Carcinoma Prevention: Emphasis on Secondary Prevention and Its Translational Challenges. <i>Journal of Clinical Medicine</i> , 2020, 9, 3817.	1.0	27
70	Assessment of Proliferation and Cytotoxicity in a Biomimetic Three-Dimensional Model of Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2015, 100, 414-421.	0.7	25
71	Epigallocatechin Gallate Induces Hepatic Stellate Cell Senescence and Attenuates Development of Hepatocellular Carcinoma. <i>Cancer Prevention Research</i> , 2020, 13, 497-508.	0.7	24
72	Why cancer at the primary site and in the lymph nodes contributes to the risk of cancer death. <i>Cancer</i> , 2009, 115, 5084-5094.	2.0	23

#	ARTICLE	IF	CITATIONS
73	STAT3 is a key transcriptional regulator of cancer stem cell marker CD133 in HCC. <i>Hepatobiliary Surgery and Nutrition</i> , 2016, 5, 201-203.	0.7	23
74	Tricyclic Antidepressants Promote Ceramide Accumulation to Regulate Collagen Production in Human Hepatic Stellate Cells. <i>Scientific Reports</i> , 2017, 7, 44867.	1.6	22
75	Advanced MRI of Liver Fibrosis and Treatment Response in a Rat Model of Nonalcoholic Steatohepatitis. <i>Radiology</i> , 2020, 296, 67-75.	3.6	22
76	How cancer at the primary site and in the lymph nodes contributes to the risk of cancer death. <i>Cancer</i> , 2009, 115, 5095-5107.	2.0	21
77	A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery. <i>Nature Communications</i> , 2021, 12, 5525.	5.8	21
78	Angiogenesis Inhibition Using an Oncolytic Herpes Simplex Virus Expressing Endostatin in a Murine Lung Cancer Model. <i>Cancer Investigation</i> , 2012, 30, 243-250.	0.6	19
79	Clinical Value of Radiographic Staging in Patients Diagnosed With AJCC Stage III Melanoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 506-513.	0.7	18
80	A functional polymorphism in the epidermal growth factor gene predicts hepatocellular carcinoma risk in Japanese hepatitis C patients. <i>OncoTargets and Therapy</i> , 2013, 6, 1805.	1.0	18
81	Liver reirradiation for patients with hepatocellular carcinoma and liver metastasis. <i>Practical Radiation Oncology</i> , 2018, 8, 414-421.	1.1	17
82	Treatment of intrahepatic malignancy with radiofrequency ablation. <i>Cancer</i> , 2000, 88, 2452-2463.	2.0	17
83	Genomic risk of hepatitis C-related hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 729-730.	1.8	15
84	Quantitative characterization of hepatocellular carcinoma and metastatic liver tumor by CT perfusion. <i>Cancer Imaging</i> , 2013, 13, 512-519.	1.2	15
85	Molecular Magnetic Resonance Imaging of Fibrin Deposition in the Liver as an Indicator of Tissue Injury and Inflammation. <i>Investigative Radiology</i> , 2020, 55, 209-216.	3.5	15
86	The past 60 years in liver surgery. <i>Cancer</i> , 2008, 113, 1888-1896.	2.0	14
87	<i>CD44</i> single nucleotide polymorphism and isoform switching may predict gastric cancer recurrence. <i>Journal of Surgical Oncology</i> , 2015, 112, 622-628.	0.8	14
88	Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 1831-1840.	0.9	14
89	Predictors of adjuvant treatment and survival in patients with intrahepatic cholangiocarcinoma who undergo resection. <i>American Journal of Surgery</i> , 2019, 218, 959-966.	0.9	14
90	Surgical resection versus ablation for early-stage hepatocellular carcinoma: A retrospective cohort analysis. <i>American Journal of Surgery</i> , 2019, 218, 157-163.	0.9	13

#	ARTICLE	IF	CITATIONS
91	A Shifting Paradigm in Diagnosis and Management of Hepatic Adenoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 3330-3338.	0.7	13
92	COVID-19 Pandemic and Surgical Oncology: Preserving the Academic Mission. <i>Annals of Surgical Oncology</i> , 2020, 27, 2591-2599.	0.7	12
93	Platelet and neutrophil to lymphocyte ratios predict survival in patients with resectable colorectal liver metastases. <i>American Journal of Surgery</i> , 2020, 220, 1579-1585.	0.9	12
94	Molecular Imaging with Bioluminescence and PET Reveals Viral Oncolysis Kinetics and Tumor Viability. <i>Cancer Research</i> , 2014, 74, 4111-4121.	0.4	11
95	Host Genetics Predict Clinical Deterioration in HCV-Related Cirrhosis. <i>PLoS ONE</i> , 2014, 9, e114747.	1.1	11
96	HSV-1 Viral Oncolysis and Molecular Imaging with PET. <i>Current Cancer Drug Targets</i> , 2007, 7, 175-180.	0.8	10
97	New Trends and Novel Treatment for Hepatocellular Carcinoma: A Global Perspective. <i>Oncologist</i> , 2010, 15, 1-4.	1.9	9
98	Clinical Significance of Microscopic Melanoma Metastases in the Nonhottest Sentinel Lymph Nodes. <i>JAMA Surgery</i> , 2015, 150, 465.	2.2	9
99	Hepatectomy for Solitary Hepatocellular Carcinoma: Resection Margin Width Does Not Predict Survival. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1727-1735.	0.9	9
100	Socioeconomic determinants of the surgical treatment of colorectal liver metastases. <i>American Journal of Surgery</i> , 2020, 220, 952-957.	0.9	9
101	Peroxidasin Deficiency Re-programs Macrophages Toward Pro-fibrosis Function and Promotes Collagen Resolution in Liver. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 1483-1509.	2.3	9
102	Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug Combinations. <i>Clinical Cancer Research</i> , 2017, 23, 4680-4692.	3.2	8
103	Surgical delay and mortality for primary cutaneous melanoma. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1089-1091.	0.6	8
104	Collagen-targeted molecular imaging in diffuse liver diseases. <i>Abdominal Radiology</i> , 2020, 45, 3545-3556.	1.0	7
105	Commentary on "Can we improve the morbidity and mortality associated with the associating liver partition with portal vein ligation for staged hepatectomy (ALPPS) procedure in the management of colorectal liver metastases?" <i>Surgery</i> , 2015, 157, 204-206.	1.0	6
106	Hepatocellular Carcinoma in Transplantable Child-Pugh A Cirrhotics: Should Cost Affect Resection vs Transplantation?. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1135-1142.	0.9	6
107	Molecular Magnetic Resonance Imaging of Liver Fibrosis and Fibrogenesis Is Not Altered by Inflammation. <i>Investigative Radiology</i> , 2021, 56, 244-251.	3.5	6
108	A model of breast cancer meningeal metastases: characterization with in vivo molecular imaging. <i>Cancer Gene Therapy</i> , 2019, 26, 145-156.	2.2	5

#	ARTICLE	IF	CITATIONS
109	Should Surgical Resection Be Combined with Imatinib Therapy for Locally Advanced or Metastatic Gastrointestinal Stromal Tumors?. <i>Annals of Surgical Oncology</i> , 2007, 14, 1784-1786.	0.7	4
110	â€œInfectiousâ€•Optimism for Treatment of Hepatocellular Carcinoma. <i>Molecular Therapy</i> , 2013, 21, 722-724.	3.7	4
111	Approaches to Regional Nodes in Patients With Melanoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 881-885.	0.8	4
112	Patterns of Failure and the Need for Biliary Intervention in Resected Biliary Tract Cancers After Chemoradiation. <i>Annals of Surgical Oncology</i> , 2020, 27, 5161-5172.	0.7	4
113	Size of the Largest Colorectal Liver Metastasis Is an Independent Prognostic Factor in the Neoadjuvant Setting. <i>Journal of Surgical Research</i> , 2021, 259, 253-260.	0.8	4
114	Quantitative, noninvasive MRI characterization of disease progression in a mouse model of non-alcoholic steatohepatitis. <i>Scientific Reports</i> , 2021, 11, 6105.	1.6	4
115	Hepatocellular carcinoma chemoprevention by targeting the angiotensin-converting enzyme and EGFR transactivation. <i>JCI Insight</i> , 2022, 7, .	2.3	4
116	New Techniques of Liver Surgery. <i>Seminars in Oncology</i> , 2006, 33, 39-41.	0.8	3
117	Creating and Providing Predictions of Melanoma Outcome. <i>Annals of Surgical Oncology</i> , 2010, 17, 1981-1982.	0.7	3
118	Case 23-2005. <i>New England Journal of Medicine</i> , 2005, 353, 401-410.	13.9	2
119	Emerging therapies for metastatic carcinoma to the liver. <i>Community Oncology</i> , 2006, 3, 567-573.	0.2	2
120	Are We Thinking? A Commentary on â€œels Partial-ALPPS Safer Than ALPPS? A Single-center Experienceâ€•. <i>Annals of Surgery</i> , 2015, 261, e93.	2.1	2
121	Impact of <i>EGF</i> , <i>IL28B</i> , and <i>PNPLA3</i> polymorphisms on the outcome of allograft hepatitis C: a multicenter study. <i>Clinical Transplantation</i> , 2016, 30, 452-460.	0.8	2
122	Prevention Strategies for Hepatocellular Carcinoma. <i>Molecular and Translational Medicine</i> , 2019, , 255-289.	0.4	2
123	Palliative External Beam Radiation Therapy for Hepatocellular Carcinoma With Right Atrial Tumor Thrombus. <i>Practical Radiation Oncology</i> , 2020, 10, e183-e187.	1.1	2
124	Desmoid tumor presenting 2 years after elective Roux-en-Y gastric bypass: a case report and review of the literature. <i>Journal of Surgical Case Reports</i> , 2020, 2020, rjz379.	0.2	2
125	Spontaneous Immune-Mediated Regression of Hepatocellular Carcinoma With High Tumor Mutational Burden. <i>JCO Precision Oncology</i> , 2021, 5, 1040-1043.	1.5	2
126	Detection of microscopic melanoma metastases in sentinel lymph nodes. , 1999, 86, 617.		2



#	ARTICLE	IF	CITATIONS
127	Variability in immune infiltrates and HLA expression in cholangiocarcinoma.. Journal of Clinical Oncology, 2014, 32, 230-230.	0.8	2
128	Multi-institutional phase II study of high dose, hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long term outcomes in patients (pts) with intrahepatic cholangiocarcinoma (ICC).. Journal of Clinical Oncology, 2015, 33, 4020-4020.	0.8	2
129	A multi-institutional phase II study of high-dose hypofractionated proton beam therapy (HF-PBT) for unresectable primary liver cancers: Long-term outcomes in patients (pts) with hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2016, 34, 376-376.	0.8	2
130	Ephemeral Seeds: Microembolization of Tumor Cells During Surgery. Annals of Surgical Oncology, 1999, 6, 631-632.	0.7	1
131	Prognostic Gene Signatures for Hepatocellular Carcinoma: What Are We Measuring?. Annals of Surgical Oncology, 2013, 20, 3707-3708.	0.7	1
132	Open hepatic resection in the elderly at two tertiary referral centers. American Journal of Surgery, 2021, 222, 594-598.	0.9	1
133	CD44s expression in human colon carcinomas influences growth of liver metastases. , 2000, 85, 523.		1
134	Hypofractionated radiation therapy for unresectable/locally recurrent intrahepatic cholangiocarcinoma.. Journal of Clinical Oncology, 2019, 37, 412-412.	0.8	1
135	Case 30-2010. New England Journal of Medicine, 2010, 363, 1352-1360.	13.9	0
136	Reply. Hepatology, 2015, 61, 729-730.	3.6	0
137	Whatâ€™s New in Gastric and Esophageal Cancers. Annals of Surgical Oncology, 2016, 23, 3773-3773.	0.7	0
138	ASO Author Reflections: A New Look at the Clinical Significance of MVI in Hepatocellular Carcinoma. Annals of Surgical Oncology, 2019, 26, 617-618.	0.7	0
139	ASO Author Reflections: Developing Personalized Care for Hepatocellular Adenoma Based on Subtype Classification. Annals of Surgical Oncology, 2020, 27, 3339-3340.	0.7	0
140	ASO Author Reflections: Variations and Inconsistencies in the Guidelines for the Clinical Management of Cholangiocarcinoma. Annals of Surgical Oncology, 2021, 28, 860-861.	0.7	0
141	Donâ€™t Let a Crisis Go to Waste. Annals of Surgical Oncology, 2021, 28, 4759-4761.	0.7	0
142	Abstract 1309: HSV1 oncolytic therapy for breast cancer meningeal metastases. , 2021, , .		0
143	Patient Selection, Resection, and Outcomes for Hepatocellular Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 265-269.	1.8	0
144	Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential surrogate biomarker in patients with <i>isocitrate dehydrogenase</i> mutant (<i>IDH</i>m) intrahepatic cholangiocarcinoma (ICC).. Journal of Clinical Oncology, 2013, 31, 4125-4125.	0.8	0

#	ARTICLE	IF	CITATIONS
145	Abstract 2454: Imaging pancreatic ductal adenocarcinoma using a zinc-sensitive MRI contrast agent: A novel method to detect early-stage PDAC lesions. <i>Cancer Research</i> , 2022, 82, 2454-2454.	0.4	0
146	Abstract 255: Peroxidasin deficiency recruits pro-healing macrophages into the liver and inhibits NAFLD progression to HCC. <i>Cancer Research</i> , 2022, 82, 255-255.	0.4	0